Results 241 to 250 of about 413,811 (335)

Corrigendum: Novel Genomic and Evolutionary Perspective of Cyanobacterial tRNAs

open access: yesFrontiers in Genetics, 2020
Tapan K. Mohanta   +3 more
doaj   +1 more source

RNA <i>trans</i>-splicing to rescue β-catenin: A novel approach for treating CTNNB1-Haploinsufficiency disorder. [PDF]

open access: yesMol Ther Nucleic Acids
Maruna M   +4 more
europepmc   +1 more source

Comprehensive Mapping of Functional Enhancers in Chinese Hamster Ovary Cells

open access: yesBiotechnology and Bioengineering, EarlyView.
In this study, the authors identified regions with enhancer activity in the CHO cell genome using genome‐wide and targeted STARR‐seq. The analysis revealed thousands of newly identified enhancer sequences, where some of the most active sequences could drive transgene expression at levels similar to or higher than strong viral enhancers.
María Santos   +9 more
wiley   +1 more source

Long-read DNA and RNA sequencing for inherited polyposis and colorectal cancer: cryptic intronic variants and multiple mutational mechanisms. [PDF]

open access: yesJ Med Genet
Jacobson AL   +13 more
europepmc   +1 more source

Intranuclear paraspeckle‐circular RNA TACC3 assembly forms RNA‐DNA hybrids to facilitate MASH‐related hepatocellular carcinoma growth in an m6A‐dependent manner

open access: yesCancer Communications, EarlyView.
Abstract Background Metabolic dysfunction‐associated steatohepatitis (MASH) is anticipated to become the leading cause of hepatocellular carcinoma (HCC). Accumulating evidence indicates that N6‐methyladenosine (m6A)‐modified circular RNAs (circRNAs) play key roles in tumor malignant progression.
Jingbo Fu   +22 more
wiley   +1 more source

Hidden Splicing Variants in Inherited Retinal Degeneration: Discovery and Functional Insight. [PDF]

open access: yesInvest Ophthalmol Vis Sci
Huang YS   +11 more
europepmc   +1 more source

Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation

open access: yesCancer Communications, EarlyView.
Abstract Radiopharmaceuticals are reshaping the landscape of cancer therapy, offering a unique theranostic advantage that is becoming increasingly central to precision medicine. By labeling the same molecular scaffold with different radionuclides, these agents enable seamless integration of diagnostic imaging and targeted therapy.
Jing Li   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy